Regeneron's EYLEA combination therapy fails phase 2 study in wet AMD
Regeneron Pharmaceuticals has unveiled topline results from the phase 2 CAPELLA study evaluating aflibercept co-formulated with rinucumab, an anti-platelet-derived growth factor receptor beta (anti-PDGFR-beta) antibody, in patients with neovascular age-related macular degeneration (wet AMD).
Click on this link for more information.
